Quantcast

Latest Glucagon-like peptide-1 analog Stories

2010-03-30 07:00:00

PRINCETON, N.J., March 30 /PRNewswire-FirstCall/ -- Diabetes Care published online the results of the Novo Nordisk (NVO) LEAD(TM) 6 extension study, which evaluated the efficacy and safety of switching from exenatide, which is taken twice a day, to once-daily Victoza®. Results show that when added to oral antidiabetes drugs (OADs), patients who switched from exenatide to Victoza experienced further reductions in A1c and weight loss. LEAD(TM) 6 was a 26-week randomized,...

2009-06-08 16:50:00

NEW ORLEANS, June 8 /PRNewswire/ -- Today, The Lancet published online the results of the Novo Nordisk (NVO) LEAD(TM) 6 study, a direct comparison between two products in a new class of diabetes treatments, the GLP-1 receptor agonists. Results show that patients treated with liraglutide had a statistically greater drop in A1C than those who received exenatide. The study compared liraglutide, a human GLP-1 analog, which is under investigation as a treatment for type 2 diabetes, to...

6d24fea791246d67dabacea7972588ef
2009-05-06 06:09:54

Amylin Pharmaceuticals Inc. said Tuesday that it has sought approval from the U.S. Food and Drug Administration (FDA) for its much-anticipated exenatide LAR, a once-weekly injectable diabetes treatment. The drug is an extended version of Byetta, a twice-daily injectable consisting of a version of a protein found in Gila monster saliva. Wall Street is looking to exenatide LAR to reinvigorate Amylin's sales.  Last year, sales of Byetta had plummeted 32 percent to $430.2 million due to...

2009-04-02 18:04:00

SILVER SPRING, Md., April 2 /PRNewswire-FirstCall/ -- Novo Nordisk today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the United States Food and Drug Administration (FDA) has finalized its discussions of questions related to liraglutide, a once-daily human GLP-1 analogue. The Advisory Committee voted on questions related to the risk profile of liraglutide. A majority of Advisory Committee members supported that appropriate evidence of cardiovascular safety...

2008-11-04 09:00:30

JERUSALEM, November 4 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc. (OTCBB: ORMP.OB) (http://www.oramed.com/), a developer of proprietary drug delivery systems, announced today that its poster entitled "Enteral Administration of Exenatide-4; Proof of Concept Pharmacodynamic Study in Dogs," has been accepted for presentation at the Diabetes Technology Society's Eighth Annual Meeting in Bethesda, Maryland between November 13-15, 2008. Oramed's exploratory study of enteral delivery...

2008-10-17 09:00:06

MONTREAL, Oct. 17 /PRNewswire-FirstCall/ -- Today, at the Canadian Diabetes Association Congress, physicians will get a first-time look at more detailed results from a phase 3b clinical study (LEAD(TM) 6) comparing the investigational new drug liraglutide to exenatide. The study showed that liraglutide, a human GLP-1 analog administered once daily was significantly more effective at improving blood glucose control (as measured by HbA1c) than exenatide, a GLP-1 mimetic administered twice...

2008-09-25 09:00:16

PRINCETON, N.J., Sept. 25 /PRNewswire/ -- Data from a 52-week phase 3 study (LEADTM 3) of Novo Nordisk's liraglutide, a once-daily human GLP-1 analog, were published online today in The Lancet. The study showed that liraglutide, when taken alone, produces statistically significant and sustained improvements in blood sugar control in patients with early type 2 diabetes, as compared with glimepiride, a widely used oral anti-diabetic drug. Moreover, the treatment with liraglutide led to...

2008-09-09 09:00:51

Novo Nordisk has presented data from a Phase III clinical study that demonstrated adding the investigational new drug liraglutide, a human GLP-1 analog, to metformin and rosiglitazone in the treatment of type 2 diabetes, leads to improved blood glucose lowering, weight loss, blood pressure reduction and improvements in beta-cell functioning. The Lead 4 study was a 26-week randomized trial that compared the efficacy and safety of two different doses of liraglutide (1.2mg and 1.8mg, QD) to...

2008-09-08 06:00:05

ROME, Sept. 8 /PRNewswire-FirstCall/ -- Novo Nordisk , a global healthcare company, presented data from a phase 3 clinical study (LEAD(TM) 4) today at the 44th annual meeting of the European Association for the Study of Diabetes that demonstrated adding the investigational new drug liraglutide, a human GLP-1 analog, to metformin and rosiglitazone in the treatment of type 2 diabetes, leads to improved blood glucose lowering (HbA1c), weight loss, blood pressure reduction and improvements in...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.